Metastatic Adenocarcinoma of The Pancreas is an indication for drug development with over 90 pipeline drugs currently active. According to GlobalData, preregistered drugs for Metastatic Adenocarcinoma of The Pancreas have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Metastatic Adenocarcinoma of The Pancreas compared to historical benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Metastatic Adenocarcinoma of The Pancreas overview

Metastatic adenocarcinoma is a cancer that originates in glandular cells (mucus-secreting cells) such as milk ducts, the digestive tract, or lungs and has spread or metastasized beyond the tissue in which it began. Adenocarcinomas can spread at any stage of the disease or they can lay dormant for an extended period of time before recurring in a distant location. It’s often diagnosed at an advanced stage due to minimal early symptoms. Common sites of metastasis include the liver, lungs, and abdominal cavity. Symptoms may involve jaundice, weight loss, abdominal pain, and digestive issues. Treatments aim to manage symptoms and may involve chemotherapy, targeted therapy, radiation, and sometimes surgery for specific cases. Prognosis is often challenging due to late diagnosis and the aggressive nature of the cancer, but personalized treatment plans and supportive care can help improve quality of life and extend survival.

For a complete picture of PTSR and LoA scores for drugs in Metastatic Adenocarcinoma of The Pancreas, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.